rss
Ann Rheum Dis 2000;59:257-262 doi:10.1136/ard.59.4.257
  • Extended report

Sequential changes of KL-6 in sera of patients with interstitial pneumonia associated with polymyositis/dermatomyositis

  1. Shuji Bandoha,
  2. Jiro Fujitaa,
  3. Yuji Ohtsukid,
  4. Yutaka Uedaa,
  5. Satoko Hojoa,
  6. Michiaki Tokudaa,
  7. Hiroaki Dobashia,
  8. Noriyuki Kuratab,
  9. Takeo Yoshinouchic,
  10. Nobuoki Kohnoe,
  11. Jiro Takaharaa
  1. aFirst Department of Internal Medicine, Kagawa Medical University, Kagawa, Japan, bKinashi Ohbayashi Hospital, Kagawa, cSecond Department of Internal Medichine, Medical School, Nagoya City University, Nagoya, Japan, dDepartment of Pathology, Kochi Medical School, Kochi, Japan, eSecond Department of Internal Medicine, Ehime University School of Medicine, Ehime, Japan
  1. Dr Bandoh, First Department of Internal Medicine, Kagawa Medical University, 1750–1, Miki-cho, Kita-gun, Kagawa, 761–0793, Japan (e-mail: sbandoh{at}mailbox.kms.ac.jp)
  • Accepted 10 November 1999

Abstract

OBJECTIVE KL-6 is a mucin-like high molecular weight glycoprotein, which is strongly expressed on type II alveolar pneumocytes and bronchiolar epithelial cells. It has been demonstrated that the KL-6 antigen is a useful marker for estimating the activity of interstitial pneumonia. In this study, it is hypothesised that serum KL-6 is a useful marker to evaluate the activity of interstitial pneumonia associated with polymyositis/dermatomyositis (PM/DM).

METHODS KL-6 was measured in sera in 16 patients diagnosed with PM/DM. Five had non-specific interstitial pneumonia (NSIP), three had diffuse alveolar damage (DAD), and eight had no pulmonary involvement, and 10 were normal non-smokers as a control group. The correlation was also evaluated between the KL-6 level and each clinical course in patients with pulmonary involvement associated with PM/DM. Immunohistochemical analysis using monoclonal anti-KL-6 antibody was also performed.

RESULTS KL-6 concentrations in sera of patients with interstitial pneumonia associated with PM/DM were significantly high compared with those of PM/DM without interstitial pneumonia, and normal non-smokers. KL-6 concentrations in sera in patients with DAD significantly increased compared with those of other groups. KL-6 values in sera changed according to the progression or improvement of interstitial pneumonia. Immunohistochemical study using pulmonary tissues obtained from patients with DAD demonstrated that the hyaline membrane, proliferating type II pneumocytes, bronchial epithelial cells and some endothelial cells in pulmonary veins were stained by antihuman KL-6 antibody.

CONCLUSION These data demonstrate that measurement of serum KL-6 was a useful marker to evaluate the activity of acute interstitial pneumonia associated with PM/DM.

Footnotes

    This Article

    1. Abstract
    2. Full text
    3. PDF

    Responses

    1. Submit a response
    2. No responses published

    Register for free content


    Free trial
    Individuals may register for a free 60 day online trial to all content.

    Free archive
    The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

    Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.